{"id":44590,"date":"2026-05-25T13:40:00","date_gmt":"2026-05-25T13:40:00","guid":{"rendered":"http:\/\/www.prnasia.com\/story\/archive\/4966992_AE66992_0"},"modified":"2026-05-25T13:40:00","modified_gmt":"2026-05-25T13:40:00","slug":"pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatm","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=44590","title":{"rendered":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)"},"content":{"rendered":"<br \/>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>This positive CHMP opinion is based on results from the <\/i><i>Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and <\/i><i>mFOLFOX6<\/i><i>&nbsp;demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and&nbsp; progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the risk of death by 51% vs <\/i><i>chemotherapy <\/i><i>with or without bevacizumab <\/i><\/li>\n<li><i>The European Commission decision is expected later this year. <\/i><i>If approved, the regimen will be the first and only combination with BRAF-targeted therapy approved for the first-line treatment of adult patients with BRAF<sup>V600E<\/sup>-mutant metastatic colorectal cancer <\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">CASTRES, France<\/span>, <span class=\"legendSpanClass\">May 25, 2026<\/span> \/PRNewswire\/ &#8212;&nbsp;Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the approval of BRAFTOVI<sup>&reg; <\/sup>(encorafenib) in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with <i>BRAF<\/i><sup>V600E<\/sup>-mutant metastatic colorectal cancer (mCRC). The positive opinion will be submitted to the European Commission (EC) with a decision on EU marketing authorisation expected later this year.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p style=\"TEXT-ALIGN: center; WIDTH: 100%\"> <a href=\"https:\/\/mma.prnasia.com\/media2\/2987142\/Pierre_Fabre_Lab_CHMP_Opinion.pdf?p=original\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color: #0000FF\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2987142\/Pierre_Fabre_Lab_CHMP_Opinion.pdf?p=pdfthumbnail\" title=\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI&reg; (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)\" alt=\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI&reg; (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)\" \/> <\/a> <br \/><span>Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI&reg; (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)<\/span><\/p>\n<\/p><\/div>\n<p>Eric Ducournau, Chief Executive Officer, Pierre Fabre Laboratories, said: &quot;Today&#8217;s positive CHMP opinion marks an important step towards a targeted approach for patients with <i>BRAF<\/i><sup>V600E<\/sup>-mutant metastatic colorectal cancer. If approved, it would be the only approved targeted therapy in the EU for this patient population in the first-line setting. This milestone reflects Pierre Fabre Laboratories&#8217; commitment to advancing meaningful innovation in oncology and to working in close partnership with the scientific and medical community to address areas of high unmet need.&quot;<\/p>\n<p>The CHMP positive opinion is based on results from the Phase 3 BREAKWATER trial which assessed the efficacy and safety of BRAFTOVI<sup>&reg;<\/sup> in combination with cetuximab and mFOLFOX6 in patients with previously untreated <i>BRAF<\/i><sup>V600E<\/sup>-mutant&nbsp;mCRC, compared with oxaliplatin-based chemotherapy, with or without bevacizumab.<\/p>\n<p>The regimen of BRAFTOVI<sup>&reg;<\/sup> in combination with cetuximab and mFOLFOX6 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy with or without bevacizumab&nbsp;(median PFS 12.8 vs. 7.1 months; hazard ratio [HR] 0.53; 95% confidence interval [CI], 0.41 to 0.68; P&lt;0.001), and demonstrated a statistically significant improvement in the dual primary endpoint of ORR in the primary analysis set.<\/p>\n<p>Contact: <a href=\"mailto:laure.sgandurra@pierre-fabre.com\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color: #0000FF\">laure.sgandurra@pierre-fabre.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and mFOLFOX6&nbsp;demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and&nbsp; progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the risk of death by [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-44590","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=44590\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog\" \/>\n<meta property=\"og:description\" content=\"This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and mFOLFOX6&nbsp;demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and&nbsp; progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the risk of death by [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=44590\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T13:40:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)\",\"datePublished\":\"2026-05-25T13:40:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590\"},\"wordCount\":448,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2986842\\\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590\",\"name\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2986842\\\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\",\"datePublished\":\"2026-05-25T13:40:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2986842\\\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2986842\\\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=44590#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=44590","og_locale":"en_US","og_type":"article","og_title":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog","og_description":"This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and mFOLFOX6&nbsp;demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and&nbsp; progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the risk of death by [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=44590","og_site_name":"My Blog","article_published_time":"2026-05-25T13:40:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=44590#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)","datePublished":"2026-05-25T13:40:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590"},"wordCount":448,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=44590","url":"https:\/\/transmediavictoria.net.au\/?p=44590","name":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600","datePublished":"2026-05-25T13:40:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=44590#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=44590"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=44590#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2986842\/Pierre_Fabre_Oncology_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=44590#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/44590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44590"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/44590\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}